keyword
MENU ▼
Read by QxMD icon Read
search

Infliximab

keyword
https://www.readbyqxmd.com/read/27931515/autologous-adipose-derived-mesenchymal-stromal-cells-for-the-treatment-of-psoriasis-vulgaris-and-psoriatic-arthritis-a-case-report
#1
Miguel M De Jesus, Jayson S Santiago, Camille V Trinidad, Melvin E See, Kimberly R Semon, Manuel O Fernandez, Francisco S Chung
Psoriasis is a dermatologic disease of immune origins with no definitive cure. We report the Makati Medical Center experience of utilizing autologous mesenchymal stromal cells (MSCs) for one patient with psoriasis vulgaris (PV) and another with psoriatic arthritis (PA). Patients were educated and gave informed consent, according to the principles of the Declaration of Helsinki. The protocol was approved by the Cellular Transplantation Ethics Committee of the Makati Medical Center. Autologous MSCs were cultured from lipoaspirate and expanded in a clean room class 100 facility (Cellular Therapeutics Center, Makati Medical Center)...
November 2016: Cell Transplantation
https://www.readbyqxmd.com/read/27931158/drug-survival-on-tumour-necrosis-factor-inhibitors-in-patients-with-rheumatoid-arthritis-in-finland
#2
K J Aaltonen, J T Joensuu, L Pirilä, M Kauppi, T Uutela, T Varjolahti-Lehtinen, T Yli-Kerttula, P Isomäki, D Nordström, T Sokka
OBJECTIVE: A systematic review found that an average of 27% of rheumatoid arthritis (RA) patients using tumour necrosis factor (TNF) inhibitors discontinue their treatment within 1 year. The aim of this study was to assess drug survival on TNF inhibitors among patients with RA. METHODS: Patients were identified from the National Register for Biologic Treatment in Finland (ROB-FIN), which is a longitudinal cohort study established to monitor the effectiveness and safety of biologic drugs in rheumatic diseases...
December 8, 2016: Scandinavian Journal of Rheumatology
https://www.readbyqxmd.com/read/27930804/increased-mitochondrial-ros-generation-mediates-the-loss-of-pvat-anticontractile-effect-in-hfd-treated-obese-mice
#3
Rafael Menezes da Costa, Rafael S Fais, Carlos R P Dechandt, Paulo Louzada-Junior, Luciane C Alberici, Núbia S Lobato, Rita C Tostes
Obesity is associated with structural and functional changes in the perivascular adipose tissue (PVAT), favoring the release of reactive oxygen species (ROS), vasoconstrictor and proinflammatory factors. Tumor necrosis factor alpha (TNF-α) induces vascular dysfunction and is produced by the PVAT. We tested the hypothesis that obesity-associated PVAT dysfunction is mediated by augmented mitochondrial ROS (mROS) generation due to increased TNF-α production in this tissue. Aortae from high fat diet (HFD)-fed obese mice displayed increased contractions to phenylephrine (PE) and loss of PVAT anticontractile effect...
December 8, 2016: British Journal of Pharmacology
https://www.readbyqxmd.com/read/27930739/heterogeneity-in-comparisons-of-discontinuation-of-tumor-necrosis-factor-antagonists-in-rheumatoid-arthritis-a-meta-analysis
#4
Anat Fisher, Ken Bassett, Gautam Goel, Dana Stanely, M Alan Brookhart, Hugh R Freeman, James M Wright, Colin R Dormuth
OBJECTIVE: We did a systematic review of studies comparing discontinuation of tumor necrosis factor alpha (TNF) antagonists in rheumatoid arthritis (RA) patients, pooled hazard ratios and assessed clinical and methodological heterogeneity. METHODS: We searched MEDLINE and EMBASE until June 2015 for pairwise hazard ratios for discontinuing infliximab, etanercept, and adalimumab from cohorts of RA patients. Hazard ratios were pooled using inverse variance weighting and random effects estimates of the combined hazard ratio were obtained...
2016: PloS One
https://www.readbyqxmd.com/read/27929524/rapid-test-for-infliximab-drug-concentration-allows-immediate-dose-adaptation
#5
Thomas Van Stappen, Lize Bollen, Niels Vande Casteele, Konstantinos Papamichael, Gert Van Assche, Marc Ferrante, Séverine Vermeire, Ann Gils
OBJECTIVES: Therapeutic drug monitoring of infliximab improves treatment outcomes, but available assays to monitor infliximab lack speed to implement treatment algorithms immediately. Our aim is to validate a rapid, lateral flow-based assay (LFA) for quantitative determination of infliximab and to assess thresholds associated with mucosal healing in patients with ulcerative colitis. METHODS: Samples (n=190) from 29 anti-tumor necrosis factor naive patients with ulcerative colitis starting infliximab induction therapy between June 2010 and February 2012 were prospectively collected...
December 8, 2016: Clinical and Translational Gastroenterology
https://www.readbyqxmd.com/read/27927829/lesson-of-the-month-1-lobar-pulmonary-consolidation-in-an-immunocompromised-host
#6
Daniel J Reynolds, Carl A Andersen, Sumedh S Hoskote, Hee Eun Lee, Aditya Raghunathan, Sanjay Kalra, Andrew H Limper
A 19-year-old male with a history of idiopathic panuveitis, currently taking methotrexate and infliximab, presented to our institution with 6 weeks of cough, dyspnoea and fevers. He had failed outpatient antimicrobial therapy. Computerised tomography (CT) of the chest revealed the presence of a lobar pneumonia and he was treated with broad spectrum antibiotics, which did not improve his symptoms. Bronchoalveolar lavage was performed with a transbronchial lung biopsy because of the diagnostic uncertainty of the patient's presentation...
December 2016: Clinical Medicine: Journal of the Royal College of Physicians of London
https://www.readbyqxmd.com/read/27924644/risk-of-malignancies-using-anti-tnf-agents-in-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis-a-systematic-review-and-meta-analysis
#7
Stefanos Bonovas, Silvia Minozzi, Theodore Lytras, Marien González-Lorenzo, Valentina Pecoraro, Silvia Colombo, Ilaria Polloni, Lorenzo Moja, Michela Cinquini, Valentina Marino, Delia Goletti, Andrea Matucci, Giuliano Tocci, Giuseppe Maria Milano, Raffaele Scarpa, Fabrizio Cantini
Malignancies have been reported in patients with rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis, treated with anti-tumour necrosis factor (anti-TNF) agents. Areas covered: We conducted a systematic review of randomized controlled trials (RCTs) to determine the effect of anti-TNF agents on the occurrence of cancer (any type). Literature databases were searched up to May 2014 to identify relevant studies that evaluated adalimumab, certolizumab, etanercept, golimumab, or infliximab, compared with placebo or no treatment...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27924643/risk-of-infections-using-anti-tnf-agents-in-rheumatoid-arthritis-psoriatic-arthritis-and-ankylosing-spondylitis-a-systematic-review-and-meta-analysis
#8
Silvia Minozzi, Stefanos Bonovas, Theodore Lytras, Valentina Pecoraro, Marien González-Lorenzo, Anan Judina Bastiampillai, Eugenia Maria Gabrielli, Andrea Carlo Lonati, Lorenzo Moja, Michela Cinquini, Valentina Marino, Andrea Matucci, Giuseppe Maria Milano, Giuliano Tocci, Raffaele Scarpa, Delia Goletti, Fabrizio Cantini
Five anti-tumor necrosis factor (anti-TNF) agents have received regulatory approval for use in rheumatology: adalimumab, golimumab, infliximab, certolizumab, and etanercept. Apart from their well-documented therapeutic value, it is still uncertain to what extent they are associated with an increased risk of infectious adverse events. Areas covered: We conducted a systematic review and meta-analysis of published randomized studies to determine the effect of anti-TNF drugs on the occurrence of infectious adverse events (serious infections; tuberculosis; opportunistic infections; any infection)...
December 2016: Expert Opinion on Drug Safety
https://www.readbyqxmd.com/read/27920647/febrile-neutropenia-with-thrombocytopenia-after-infliximab-induction-in-a-patient-with-ulcerative-colitis
#9
Gustavo Gomez, Shifa Umar, Mohammad Bilal, Cristina Strahotin, Kofi Clarke
A 34-year-old female with left-sided ulcerative colitis (UC) developed severe febrile neutropenia/thrombocytopenia soon after infliximab induction therapy. There was no other plausible cause of the cell line abnormalities other than an accurate temporal association with infliximab administration. Supportive care, broad-spectrum antibiotic, and single dose of filgrastim was given on day 5 of admission due to persistently low absolute neutrophil count and fevers. The cell lines recovered, fever resolved and the patient made a complete clinical recovery...
September 2016: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/27920646/successful-treatment-of-small-intestinal-bleeding-in-a-crohn-s-patient-with-noncirrhotic-portal-hypertension-by-transjugular-portosystemic-shunt-placement-and-infliximab-treatment
#10
Benjamin Heimgartner, Heather Dawson, Andrea De Gottardi, Reiner Wiest, Jan Hendrik Niess
Small intestinal bleeding in Crohn's disease patients with noncirrhotic portal hypertension and partial portal and superior mesenteric vein thrombosis is a life-threatening event. Here, a case is reported in which treatment with azathioprine may have resulted in nodular regenerative hyperplasia, portal hypertension and portal vein thrombosis. The 56-year-old patient with Crohn's disease developed nodular regenerative hyperplasia under treatment with azathioprine. He was admitted with severe bleeding. Gastroscopy showed small esophageal varices without bleeding stigmata...
September 2016: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/27920644/severe-acute-respiratory-distress-syndrome-during-infliximab-therapy-in-a-patient-with-crohn-disease
#11
Johanna Schoehl, Nicolae-Catalin Mechie, Harald Schwoerer, Onnen Moerer, Michael Quintel, Cordula Buck, Volker Ellenrieder, Albrecht Neesse, Ahmad Amanzada
The occurrence of a noninfectious interstitial lung disease is a rare but life-threatening side effect of infliximab, an antitumor necrosis factor alpha antibody. The following case report of a patient with Crohn disease shows an extremely dramatic progression to a severe acute respiratory distress syndrome.
September 2016: Case Reports in Gastroenterology
https://www.readbyqxmd.com/read/27920336/reasons-for-discontinuation-and-adverse-effects-of-tnf%C3%AE-inhibitors-in-a-cohort-of-patients-with-rheumatoid-arthritis-and-ankylosing-spondylitis
#12
María Henar García-Lagunar, María Rocío Gutiérrez-Cívicos, María Sergia García-Simón, Pablo Conesa-Zamora, Enrique Jimenez-Santos, Pedro Cano-Vivar, Andrés García-Márquez, Iris Muñoz-García, Alice Charlotte Viney
BACKGROUND: The introduction of anti-tumor necrosis factor α (anti-TNFα) drugs has improved the clinical outcomes in rheumatoid arthritis (RA) and ankylosing spondylitis (AS). However, these drugs may cause adverse effects that motivate a change in or discontinuation of the treatment. OBJECTIVE: To evaluate the causes of discontinuation or changes in the dosage regimen in a cohort of patients with RA and AS treated with infliximab, adalimumab, etanercept, and golimumab under clinical practice conditions...
December 5, 2016: Annals of Pharmacotherapy
https://www.readbyqxmd.com/read/27919316/corrigendum-adalimumab-etanercept-infliximab-certolizumab-pegol-golimumab-tocilizumab-and-abatacept-for-the-treatment-of-rheumatoid-arthritis-not-previously-treated-with-disease-modifying-antirheumatic-drugs-and-after-the-failure-of-conventional-disease-modifying
#13
Matt Stevenson, Rachel Archer, Jon Tosh, Emma Simpson, Emma Everson-Hock, John Stevens, Monica Hernandez-Alava, Suzy Paisley, Kath Dickinson, David Scott, Adam Young, Allan Wailoo
No abstract text is available yet for this article.
November 2016: Health Technology Assessment: HTA
https://www.readbyqxmd.com/read/27918378/safety-of-infliximab-following-live-virus-vaccination-in-kawasaki-disease-patients
#14
Aaron M Lee, Jane C Burns, Adriana H Tremoulet
No published data are available regarding infliximab use in Kawasaki Disease (KD) patients with recent live virus vaccination. We investigated 38 acute KD patients who received infliximab within 90 days of receiving MMR, VZV, or Rotavirus vaccines. There were no adverse events or serious infections, which suggests that infliximab use in acute KD patients with recent live viral vaccinations is safe.
December 1, 2016: Pediatric Infectious Disease Journal
https://www.readbyqxmd.com/read/27914593/systemic-and-localized-infection-by-candida-species-in-patients-with-rheumatic-diseases-receiving-anti-tnf-therapy
#15
Nadia E Aikawa, Daniela T A Rosa, Gilda M B Del Negro, Julio C B Moraes, Ana C M Ribeiro, Carla Gonçalves Saad, Clovis A Silva, Eloisa Bonfá
OBJECTIVE: To evaluate the prevalence of systemic and localized infection by Candida species and its possible association with demographic, clinical and laboratory manifestations and therapy in patients with rheumatic diseases taking TNF blockers. METHODS: Consecutive patients with rheumatic diseases receiving anti-TNF agents were included. The following risk factors up to four weeks prior to the study were analyzed: use of antibiotics, immunosuppressant drugs, hospitalization and invasive procedures...
November 2016: Revista Brasileira de Reumatologia
https://www.readbyqxmd.com/read/27914574/biological-therapies-immunomodulatory-drugs-worsening-of-psoriasis-and-rebound-effect-new-evidence-of-similitude
#16
REVIEW
Marcus Zulian Teixeira
BACKGROUND: Employing the secondary action or adaptative reaction of the organism as therapeutic response, homeopathy uses the treatment by similitude (similia similibus curentur) administering to sick individuals the medicines that caused similar symptoms in healthy individuals. Such homeostatic or paradoxical reaction of the organism is scientifically explained through the rebound effect of drugs, which cause worsening of symptoms after withdrawal of several palliative treatments. Despite promoting an improvement in psoriasis at the beginning of the treatment, modern biological therapies provoke worsening of the psoriasis (rebound psoriasis) after discontinuation of drugs...
November 2016: Homeopathy: the Journal of the Faculty of Homeopathy
https://www.readbyqxmd.com/read/27913244/higher-risk-of-hospitalization-and-serious-infection-among-patients-with-ulcerative-colitis-treated-with-adalimumab-compared-with-infliximab-in-a-nationwide-study
#17
Siddharth Singh, Nynne Nyboe Andersen, Mikael Andersson, Edward V Loftus, Tine Jess
BACKGROUND & AIMS: We compared the effectiveness and safety of infliximab and adalimumab in biologic-naïve patients with ulcerative colitis (UC), in a nationwide register-based propensity score-matched study of patients in Denmark. METHODS: We collected data from 1719 adults with UC, 15-75 years old, in Denmark who were treated with either infliximab or adalimumab as their first biologic agent. We compared rates of all-cause hospitalization, UC-related hospitalization, major abdominal surgery, and serious infections after a variable 2:1 propensity score matching, accounting for baseline clinical characteristics, disease severity, healthcare use, and use of UC-related medications...
November 29, 2016: Clinical Gastroenterology and Hepatology
https://www.readbyqxmd.com/read/27910149/editorial-adalimumab-or-infliximab-as-monotherapy-or-in-combination-with-an-immunomodulator-in-the-treatment-of-crohn-s-disease
#18
EDITORIAL
B Christensen, M P Sparrow
No abstract text is available yet for this article.
January 2017: Alimentary Pharmacology & Therapeutics
https://www.readbyqxmd.com/read/27909436/evaluation-of-anti-inflammatory-effects-of-steroids-and-arthritis-related-biotherapies-in-an-in-vitro-coculture-model-with-immune-cells-and-synoviocytes
#19
Mélissa Noack, Ndiémé Ndongo-Thiam, Pierre Miossec
BACKGROUND: During rheumatoid arthritis (RA), steroids and biotherapies are used alone and combined. Efficacy has been established in clinical trials but their differential effects at the cellular level are less documented. The aim was to study these cellular effects using an in vitro model with synoviocytes interacting with peripheral blood mononuclear cells (PBMC) to reproduce the interactions in the RA synovium. METHODS: Activated-PBMC were cocultured with RA synoviocytes during 48 h...
2016: Frontiers in Immunology
https://www.readbyqxmd.com/read/27904147/penile-constitutive-nitric-oxide-synthase-expression-in-rats-exposed-to-unpredictable-chronic-mild-stress-role-of-inflammation
#20
T D Şahin, Y Yazır, T Utkan, S S Göçmez, D Bayramgürler
Chronic psychological stress cause erectile dysfunction (ED). Considering recent evidence that tumor necrosis factor-α (TNF-α) levels are increased in serum of patients with ED, the present study investigated the effects of infliximab (a TNF-α blocker) on endothelial nitric oxide synthase (eNOS) and neuronal NOS (nNOS) immunoreactivity of rat penile corpus cavernosum in unpredictable chronic mild stress (UCMS). Male adult rats were randomly divided into three groups (n=8 per group): Control, UCMS and UCMS+infliximab...
December 1, 2016: International Journal of Impotence Research
keyword
keyword
1757
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"